Physician
General Surgery
Dr. Brian I. Carr, MD
|
|
Give Review
Dr. Brian I. Carr works in the field of General Surgery. He researched medicine at Imperial College London School of Medicine. Brian I. Carr is also published. He has 76 publications published. The lastest publication: "Erratum to: Low Alpha-Fetoprotein Levels Are Associated with Improved Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Low Alpha-Fetoprotein Levels Are Associated with Improved Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis.
- Erratum to: Low Alpha-Fetoprotein Levels Are Associated with Improved Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis.
- Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients.
- Guest editorial: platelets and Cancer.
- Modulation of Doxorubicin Mediated Growth Inhibition of Hepatocellular Carcinoma Cells by Platelet Lysates.
- Low alpha-fetoprotein HCC and the role of GGTP.
- A Systematic Review of Randomized Controlled Trials Testing the Efficacy of Psychosocial Interventions for Gastrointestinal Cancers.
- Macro- and Micro-environmental Factors in Clinical Hepatocellular Cancer.
- Features of massive hepatocellular carcinomas.
- Significance of platelet and AFP levels and Liver function parameters for HCC size and survival.
- Hepatocellular Carcinoma Size: Platelets, γ-Glutamyl Transpeptidase, and Alkaline Phosphatase.
- Thrombocytosis and hepatocellular carcinoma.
- Phenotypic Categorization and Profiles of Small and Large Hepatocellular Carcinomas.
- Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery.
- Prospective randomized trial of hepatic artery chemotherapy with Cisplatin and Doxorubicin, with or without lipiodol in the treatment of advanced stage hepatocellular ...
- c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition.
- Peripheral Blood Lymphocyte Depletion After Hepatic Arterial (90)Yttrium Microsphere Therapy for Hepatocellular Carcinoma.
- Small HCCs Identified by Screening.
- Cell membrane and cytoplasmic epidermal growth factor receptor expression in Pancreatic ductal adenocarcinoma.
- Differential Effects of Vitamin K1 on AFP and DCP Levels in Patients with Unresectable HCC and in HCC Cell Lines.
- Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.
- HCC in older patients.
- Hepatic artery chemoembolization for the treatment of Liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients.
- Pain at presentation and survival in hepatocellular carcinoma.
- Involvement of receptor tyrosine phosphatase DEP-1 mediated PI3K-cofilin signaling pathway in sorafenib-induced cytoskeletal rearrangement in hepatoma cells.
- Sorafenib combined vitamin K induces apoptosis in human pancreatic Cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways.
- Cancer-related symptom clusters, eosinophils, and survival in hepatobiliary Cancer: an exploratory study.
- Network-based analysis of survival for unresectable hepatocellular carcinoma.
- Regional hepatic therapy for Cancer.
- Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort...
- Welcome to the journal of Gastrointestinal Cancer, 2010.
- Tumor and Liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study.
- Involvement of ATM-mediated Chk1/2 and JNK kinase signaling activation in HKH40A-induced cell growth inhibition.
- Hepatobiliary effects of 90yttrium microsphere therapy for unresectable hepatocellular carcinoma.
- Integrin alpha5-induced EGFR activation by prothrombin triggers hepatocyte apoptosis via the JNK signaling pathway.
- Measuring post-traumatic growth in people diagnosed with hepatobiliary Cancer: directions for future research.
- Chemo-embolization for unresectable hepatocellular carcinoma with different sizes of embolization particles.
- Gender-based outcomes differences in unresectable hepatocellular carcinoma.
- Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis.
- Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience.
- Grb2-associated binder-1 plays a central role in the hepatocyte growth factor enhancement of hepatoma growth inhibition by K vitamin analog compound 5.
- Posttraumatic growth, immunity and survival in patients with hepatoma.
- Depression, immunity, and survival in patients with hepatobiliary carcinoma.
- Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the ...
- Preliminary results of an individually tailored psychosocial intervention for patients with advanced hepatobiliary carcinoma.
- H32, a non-quinone sulfone analog of vitamin K3, inhibits human hepatoma cell growth by inhibiting Cdc25 and activating ERK.
- Antitumor activity of JS-K [O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and related O2-aryl diazeniumdiolates in vitro and in ...
- Phosphorylation regulates Myc expression via prolonged activation of the mitogen-activated protein kinase pathway.
- PM-20, a novel inhibitor of Cdc25A, induces extracellular signal-regulated kinase 1/2 phosphorylation and inhibits hepatocellular carcinoma growth in vitro and in vivo.
- Outcome of 1000 liver Cancer patients evaluated at the UPMC Liver Cancer Center.
- Sexual functioning in patients with hepatocellular carcinoma.
- Cdc25A and ERK interaction: EGFR-independent ERK activation by a protein phosphatase Cdc25A inhibitor, compound 5.
- Hepatocyte growth factor enhances protein phosphatase Cdc25A inhibitor compound 5-induced hepatoma cell growth inhibition via Akt-mediated MAPK pathway.
- Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy.
- Novel hydroxyl naphthoquinones with potent Cdc25 antagonizing and growth inhibitory properties.
- Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with Liver toxicities.
- Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis.
- The effects of hepatic artery chemotherapy on viral hepatitis in patients with hepatocellular carcinoma.
- Hepatocellular carcinoma: current management and future trends.
- Yttrium-90 microspheres for the treatment of hepatocellular carcinoma.
- Characteristics of hepatocellular carcinoma in a high arsenicism area in Taiwan: a case-control study.
- NAD(P)H:quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors.
- Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients.
- JS-K, a novel non-ionic diazeniumdiolate derivative, inhibits Hep 3B hepatoma cell growth and induces c-Jun phosphorylation via multiple MAP kinase pathways.
- Binding and inhibition of Cdc25 phosphatases by vitamin K analogues.
- To transplant, or not to transplant?
- Persistent ERK phosphorylation negatively regulates cAMP response element-binding protein (CREB) activity via recruitment of CREB-binding protein to pp90RSK.
- Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma.
- K vitamins, PTP antagonism, and cell growth arrest.
- Yttrium-90 microspheres: radiation therapy for unresectable liver Cancer.
- Transient and sustained ERK phosphorylation and nuclear translocation in growth control.
- Identification of epidermal growth factor receptor as a target of Cdc25A protein phosphatase.
- EGFR-independent activation of ERK1/2 mediates growth inhibition by a PTPase antagonizing K-vitamin analog.
- Hepatocellular carcinoma in noncirrhotic Liver: CT, clinical, and pathologic findings in 39 U.S. residents.
- Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines.
Schools
St Mary39s Hospital Medical School University Of London University Of London
Bolingbroke Hospital United Kingdom
King Edward VII Hospital United Kingdom
Medical Research Council United Kingdom
St Peter39s Hospital United Kingdom
Royal Marsden United Kingdom
University Of Wisconsin Medical School
Conditions Treated
- Anemia
- Breast Cancer
- Liver Cancer
- Lymphoma
- View All
Doctors Specialties
- Oncology
- General Surgery
Accepted Insurances
Education
-
University of Wisconsin -
Imperial College London School of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Chiaka O. Abara, MD |
|
|
Dr. Henry P. Schoonyoung, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Reginald C. Anunobi, MD |
|
|
Dr. Omar A. Khaleel, MD |
|
|
Dr. John Y. Chung, MD |
|
Dr. Takami Sato, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James J. Perry, MD |
|
|
Dr. Patrick K. Kim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jo Buyske, MD
This Doctor is OpenDoctor Recommended.
|